Haloperidol
Verificar en psychonaut
Haloperidol
Verificar en isomerdesign
Haloperidol
Verificar en pubchem
Haloperidol
Verificar en drugmap
Haloperidol
Verificar en drugmap
Haloperidol
Verificar en wiki
Data
InChI: InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
Sinónimos: n--boc-l-asparagine,MRF-0000027,NSC-615296,R-1625,Spectrum4_000570,HMS2234P08,KBioSS_002395, Sigaperidol,AKOS000280660,SPBio_001236, Serenace (TN),R 1625,Haloperidol (JP17/USP/INN),NCGC00023875-04, Linton,BRD-K67783091-001-04-8, Aloperidolo, Mixidol,Poly[2-methoxy-5-(3',7'-dimethyloctyloxy)-1,4-phenylenevinylene],A899749, Lealgin compositum,BRN 0331267,Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro-,KBio2_004958,BH166165,Spectrum3_000448,NCGC00023875-07, Haloperidol [USAN:INN:BAN:JAN],Bioperidolo, Aloperidin (TN), Peridol,HMS2089M15,HMS2095G12,Sigaperidol,Probes1_000255,GTPL86,NCGC00015500-06,CCG-36042, Dozix,1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, Ulcolind,HMS3657I13,Aloperidolo [DCIT],BSPBio_002096,NCGC00015500-13, McN-JR-1625,FT-0669101,1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-,Haloperidol (Haldol),Haloperidol, United States Pharmacopeia (USP) Reference Standard, Haldol,SW196557-4,N1910,Halopoidol,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl) -1-butanone,BIDD:GT0128, Haloperidol (JP15/USP),NCGC00023875-02, Keselan,KBio2_007526,CCG-39111,Duraperidol,Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-,Haloperidol-[Chlorophenyl-d4],SDCCGSBI-0050565.P005, Galoperidol,5-21-02-00377 (Beilstein Handbook Reference),NCGC00015500-14,H0912,Tox21_110162_1,AB00052008_24,Ulcolind, Aloperidolo [DCIT],BRD-K67783091-001-05-5, Bioperidolo (TN),EINECS 200-155-6,4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone,Haldol (TN),Biomol-NT_000035, Brotopon,NSC170973,HALOPERIDOL [USAN],NINDS_000654, H 1512,NCGC00015500-10,4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone,KBio2_001341,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;propionate(HCl),NCGC00261268-01,MLS000028450, Duraperidol (TN),NCGC00015500-07,VU0239704-10,Serenace,Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Serenase (TN),KBio3_001316,Pernox,ZINC537822,NCGC00015500-15,HALOPERIDOL [MI],4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one,NCGC00015500-17, Serenelfi,VESALIUM COMPONENT HALOPERIDOL,NCGC00015500-01,KBioGR_000980, Dozic (TN),4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one, Halopidol, Aldo,HALOPERIDOL DECANOATE IMPURITY G [EP IMPURITY],Galoperidol,Spectrum5_000788,cMAP_000037, Sernas,Halol,HALOPERIDOL [WHO-DD],Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard,HALOPERIDOL [ORANGE BOOK],Prestwick1_000115, Serenace,Prestwick3_000115,HALOPERIDOL [INN],IDI1_000654,HALOPERIDOL [MART.],SR-01000003076-11, Halol,Haloperidol 1.0 mg/ml in Methanol,Epoxy resins,Halosten,Serenelfi,Halopal,WLN: T6NTJ A3VR DF& DQ DR DG,52-86-8,Aldo,KBio1_000654,Sernas,NSC757054,Q251347, Halosten,NCGC00015500-19, Haldol La,Haldol,Aloperidolo [Italian], Halosten (TN),Opera_ID_446,NCGC00015500-12,NSC 615296,BPBio1_001231,Probes2_000296,SPECTRUM1500325,Haloperidol, 1,LNEPOXFFQSENCJ-UHFFFAOYSA-,HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP IMPURITY], Aloperidolo [Italian], Sernel,KBio2_006477,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one,Haloperidol decanoate impurity, haloperidol-,AC-19691,Lopac0_000583,NCGC00023875-05,L000288,Lealgin compositum,starbld0018801, Einalon S,BSPBio_000130,DSSTox_RID_79117,AB00052008,NSC-757054,NCGC00023875-09,4-[4-(para-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone,D00136,AC250,Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-, Haloperidolum [INN-Latin],Aloperidol, Pekuces,Poly[[2-[(3,7-dimethyloctyl)oxy]-5-methoxy-1,4-phenylene]-1,2-ethenediyl],DivK1c_000654,MLS001146904,NCGC00015500-09,Haloperidol [USAN:USP:INN:BAN:JAN], Halidol,4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone, R-1625,STR04750,NCGC00015500-11,KBioGR_002390,Prestwick_250, Apo-Haloperidol, Serenase,Aloperidolo,NCGC00023875-08, Linton (TN),Haloperidol for peak identification, Keselan (TN), Haloperidol (JP15/USP/INN),gamma-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone,Haloperidol, European Pharmacopoeia (EP) Reference Standard,Sernel, Brotopon (TN), Haloperido,KBio3_002869,4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone,UNII-J6292F8L3D,gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone, Dozic,Uliolind,NCGC00015500-02,SPBio_002069,Keselan, Haldol Solutab,CS-1971,Prestwick2_000115,AB00052008-21,HMS3712G12,4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone,EU-0100583,Spectrum_000861,CHEMBL54,Haldol Solutab, Haldol (TN),4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone,FT-0697842,4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one,haloperidol,NCGC00015500-24,SC 170973,Tox21_500583,H 1512,1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-,Haloperidolum,.gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone,QTL1_000042,Novo-Peridol,DSSTox_GSID_34150,Aloperidin, Bioperidolo,AB00052008-22,Einalon S,BRD-K67783091-003-03-6,4-(4-(para-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone, Aloperidon,HMS3261F08,BPBio1_000144,NCGC00015500-32,CAS-52-86-8,KBio2_002390,gamma-[4-(p-chlorophenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone,DB00502,HALOPERIDOL [EP MONOGRAPH],LP00583,.gamma.-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone,NCGC00254503-01,Halidol,BCP33202,HALOPERIDOL [HSDB],Tox21_110162,KBioSS_001341, Pms Haloperidol,FT-0669100,Brotopon,McM-JR-1625,DTXSID4034150,HMS1920D03,Halojust,HY-14538,HMS502A16,S1920,HALOPERIDOL [USP IMPURITY],HSDB 3093,Serenase,SCHEMBL8264, Aloperidin,McN-JR-1625,AB00052008_23,HALOPERIDOLUM [WHO-IP LATIN],HMS2091J09,4'-Fluoro-4-[4-hydroxy-4-(4'-chlorophenyl)piperidino]butyrophenone, Einalon S (TN), Haloperidolum,CHA71659,Tox21_300475,Haloperidol,Neurodol, Aloperidol, Eukystol (TN),Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material,NCGC00023875-06,SMR000058303,HMS3370H11,CHEBI:5613,Tocris-0931,Haloperidol, powder,SR-01000003076-2, Halopal,NCGC00015500-08,BDBM21398,177716-59-5,HALOPERIDOL [VANDF],SBI-0050565.P004,NCGC00015500-04,Halopidol,Haloperidol for system suitability,4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone,Prestwick0_000115, Halopoidol,CCRIS 1630,STL417208,SR-01000003076,NCGC00015500-05,NCGC00016234-01, Peluces,HALOPERIDOL [USP-RS],Dozic,Pharmakon1600-01500325,Fortunan,NCGC00015500-16, Eukystol,Aloperidon,gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone,DSSTox_CID_14150,HALOPERIDOL COMPONENT OF VESALIUM,W-105791,NSC-170973, R 1625, Uliolind,HALOPERIDOL [JAN],Peluces,4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone,Haloperidolum [INN-Latin],Linton,J6292F8L3D,C01814,HMS1568G12, Pernox,Picroside-III, Halojust,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,KBio2_003909, Peluces (TN), Fortunan,Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard,Mixidol,NSC 170973,Eukystol,NCGC00015500-03,HALOPERIDOL [WHO-IP],Pekuces,AT13670, Vesalium,A0H334,Z1590789254,Lopac-H-1512,Oprea1_509923,NSC615296,HALOPERIDOL [USP MONOGRAPH],Spectrum2_001268, Sigaperidol (TN),SR-01000003076-8
Estimated data
Solubilidad: -4.201 (log(S) in mol/L prediction using SolTranNet)
Blood Brain Barrier Permeability: No (prediction using frontiersin.org)
Addictivity Prediction: 49.3% (prediction based on www.mdpi.com)
